De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease

J Crohns Colitis. 2016 Mar;10(3):371-2. doi: 10.1093/ecco-jcc/jjv206. Epub 2015 Nov 6.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / metabolism
  • Crohn Disease / drug therapy*
  • Crohn Disease / metabolism
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Monitoring
  • Feces / chemistry
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / administration & dosage*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Infliximab / administration & dosage*
  • Infliximab / therapeutic use
  • Leukocyte L1 Antigen Complex / metabolism*
  • Maintenance Chemotherapy / methods*
  • Male
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Recurrence
  • Treatment Outcome
  • Young Adult

Substances

  • Biomarkers
  • Gastrointestinal Agents
  • Leukocyte L1 Antigen Complex
  • Infliximab